SecBot SecBot
Biotech Drug Report Generated Oct 27, 2026

Victoza

NVO·NOVO NORDISK A S
BEARISH
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2010.
Why 3/10
No hard, dated binary catalyst (PDUFA, pivotal readout, AdComm) is scheduled for Victoza in the next ~12 months. The drug has been approved since 2010 and is facing established generic competition. For Novo Nordisk (NVO), Victoza is a rapidly declining legacy product contributing <1% of total revenue, making any single data point for this one drug incapable of meaningfully moving the stock.
Actionable Insight BEARISH

Victoza is a tail-end asset with no upcoming binary catalyst. For Novo Nordisk investors, watch GLP-1 class dynamics, generic liraglutide erosion is already priced in, but the FDA's shortage status (still active as of Oct 2026) could create short-term supply-driven revenue variability. The real stock drivers are semaglutide (Ozempic/Wegovy) competitive positioning and the oral Wegovy rollout, not this legacy product.

Price Chart

Loading chart...

Executive Summary

Victoza (liraglutide) is Novo Nordisk's first-generation GLP-1 receptor agonist, FDA-approved since January 2010 for type 2 diabetes (adults and children 10+) and expanded in 2017 to reduce cardiovascular risk. The drug has been a commercial blockbuster in its prime but is now deep into its decline phase: generic competition arrived in 2024 (Teva authorized generic in June, Hikma ANDA in December), and Victoza revenue fell ~45% year-over-year to DKK 3.0 billion in FY2025. For Novo Nordisk (NYSE: NVO, $38.69), Victoza represents less than 1% of total revenue, the company's massive GLP-1 franchise is now dominated by semaglutide products (Ozempic, Wegovy, Rybelsus), which generated $24.0B in 2025. No upcoming FDA catalysts or PDUFA dates exist for Victoza, and the stock's trajectory depends on Wegovy/Ozempic competitive dynamics and pipeline assets, not this mature legacy product.

How It Works

Victoza (liraglutide) is a once-daily injectible medication that mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). When blood sugar rises after eating, it sshows the pancreas to release more inslin, slows down food emptying from the stomach, and reduces appetite. This combination helps control blood sugar in people with type 2 diabetes and has been shown to lower the risk of heart attack, stroke, and cardiovascular death.

Trial Status

Victoza completed all required Phase 3 trials for initial FDA approval in 2010. A post-market cardiovascular outcomes trial (LEADER) supported the CV risk-reduction label expansion in 2017. Pediatric approval in 2019 was based on the first Phase 3 trial of a non-insulin diabetes drug in children (NEJM 2019). All patent-protected clinical development is conplete; no new pivotal trials are running for this indication.

The Two-Sided Case

▲ Bull Case4
Established safety record: liraglutide has over 16 years of real-world use and remains the only GLP-1 with a dedicated cardiovascular outcomes trial (LEADER) proving risk reduction in type 2 diabetes patients with established CVD.
FDA shortage status still active as of Oct 2026 means some patients who cannot find generic alternatives may still rely on branded Victoza, providing a modest revenue floor.
Broad label: Victoza is approved for adults, pediatric patients 10+, and carries a CV risk-reduction indication, differentiating it from some newer entrants that lack pediatric data.
Novo Nordisk's overall GLP-1 franchise (Ozempic, Wegovy, Rybelsus) generated $24.0B in 2025, so the company has massive resources to manage the Victoza decline.
▼ Bear Case4
Generic erosion accelerating: Teva launched an authorized generic in June 2024 and Hikma received FDA approval for a full ANDA generic in December 2024, driving Victoza revenue down ~45% YoY to DKK 3.0B in FY2025.
Novo Nordisk has largely moved on, the company's pipeline and commercial focus have shifted to semaglutide (Ozempic, Wegovy, Rybelsus) and next-generation obesity drugs, making Victoza a legacy product with declining investment.
Superior alternatives exist: semaglutide and tirzepatide offer better efficacy (e.g. 6.4% weight loss for liraglutide vs 15.8% for semaglutide head-to-head), so Victoza faces both branded and generic competitive pressure.
FDA still lists Victoza as in shortage (as of Sep 2026), with manufacturing delays limiting supply, but generic liraglutide is available from multiple manufacturers, so market share is shifting away from the brand.

Upcoming Catalysts

  • None scheduled. Victoza is an approved, off-patent legacy drug with no pending FDA decisions, label-expansion applications, or registrational readouts in the next ~12 months.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S COURT-RULING NVO ·Originating report

Sources · 7

Hover a chip for the title
1 drugs.com2 fda.gov3 hikma.com4 fiscal.ai5 fda.gov6 hellopharmacist.com7 transparrentpeptide.com